Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1211–59.
Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.
Wilkinson C, Clegg A, Todd O, Rockwood K, Yadegarfar ME, Gale CP, et al. Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study. Age Ageing. 2021;50(3):772–9.
Laupacis A, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–57.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305.
Article PubMed PubMed Central Google Scholar
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612–76.
Granger CB, Alexander JH, Mcmurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
Article CAS PubMed Google Scholar
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
Article CAS PubMed Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
Article CAS PubMed Google Scholar
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
Article CAS PubMed Google Scholar
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy. Chest. 2012;141(2):e44S-e88S.
Article CAS PubMed PubMed Central Google Scholar
Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):187–205.
Article CAS PubMed PubMed Central Google Scholar
De Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, De Asmundis C, et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f30–9.
Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation. Stroke. 2018;49(1):98–106.
Article CAS PubMed Google Scholar
Ibáñez L, Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, et al. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): a cross-national drug utilization study. Br J Clin Pharmacol. 2019;85(11):2524–39.
Article PubMed PubMed Central Google Scholar
Hias J, Van der Linden L, Walgraeve K, Gijsen M, Mian P, Koch BCP, et al. Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. Br J Clin Pharmacol. 2021;88:1020–30.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics—2009 update. Circulation. 2009;119(3):e21–181.
Eurostat. Ageing Europe: Looking at the lives of older people in the EU. Luxembourg: Publications Office of the European Union. 2019.
Bramer WM, Giustini D, De Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–3.
Article PubMed PubMed Central Google Scholar
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:1.
Bendayan M, Mardigyan V, Williamson D, Chen-Tournoux A, Eintracht S, Rudski L, et al. Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation. J Am Geriatr Soc. 2021;69(4):1012–8.
Bernier M, Lancrerot SL, Rocher F, Van-Obberghen EK, Olivier P, Lavrut T, et al. Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. J Geriatr Cardiol. 2019;16(11):806–11.
CAS PubMed PubMed Central Google Scholar
Bhagirath VC, Chan N, Hirsh J, Ginsberg J, de Vries TAC, Eikelboom J. Plasma apixaban levels in patients treated off label with the lower dose. J Am Coll Cardiol. 2020;76(24):2906–7.
Article CAS PubMed Google Scholar
Chaussade E, Hanon O, Boully C, Labourée F, Caillard L, Gerotziafas G, et al. Real-life peak and trough dabigatran plasma measurements over time in hospitalized geriatric patients with atrial fibrillation. J Nutr Health Aging. 2018;22(1):165–73.
Article CAS PubMed Google Scholar
Comans AL, Sennesael AL, Bihin B, Regnier M, Mullier F, de Saint-Hubert M. Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: impact on plasma drug levels. Thromb Res. 2021;201:139–42.
Article CAS PubMed Google Scholar
Gendron N, Chocron R, Billoir P, Brunier J, Camoin-Jau L, Tuffigo M, et al. Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting. Front Med. 2020;2020:7.
Gommans E, Grouls RJE, Kerkhof D, Houterman S, Simmers T, Van Der Linden C. Dabigatran trough concentrations in very elderly patients. Eur J Hosp Pharm. 2021;28(4):231–3.
Gulilat M, Keller D, Linton B, Pananos AD, Lizotte D, Dresser GK, et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombol. 2020;49(2):294–303.
Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythm. 2016;32(1):42–50.
Kampouraki E, Avery P, Biss T, Wynne H, Kamali F. Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. Br J Haematol. 2021;195(5):790–801.
Article CAS PubMed Google Scholar
Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenom Personal Med. 2018;11:43–9.
Lin SY, Kuo CH, Huang TM, Peng YF, Huang CF, Tang SC, et al. Impact of different renal function equations on direct oral anticoagulant concentrations. Sci Rep. 2021;11(1):23833.
Article CAS PubMed PubMed Central Google Scholar
Lin SY, Kuo CH, Yeh SJ, Tsai LK, Liu YB, Huang CF, et al. Real-world rivaroxaban and apixaban levels in asian patients with atrial fibrillation. Clin Pharmacol Ther. 2020;107(1):278–86.
Article CAS PubMed Google Scholar
Mavri A, Vene N, Božič-Mijovski M, Miklič M, Söderblom L, Pohanka A, et al. Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep. 2021;11(1):13908.
Article CAS PubMed PubMed Central Google Scholar
Nissan R, Spectre G, Hershkovitz A, Green H, Shimony S, Cooper L, et al. Apixaban levels in octogenarian patients with non-valvular atrial fibrillation. Drugs Aging. 2019;36(2):165–77.
Article CAS PubMed Google Scholar
Okata T, Toyoda K, Okamoto A, Miyata T, Nagatsuka K, Minematsu K. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. PLoS ONE. 2014;9:11.
Osanai H, Ajioka M, Masutomi T, Kuwayama T, Ishihama S, Sakamato Y, et al. Measurement of anti-factor xa activity in patients on apixaban for non-valvular atrial fibrillation. Circ J. 2015;79(12):2584–90.
Article CAS PubMed Google Scholar
Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al. Effect of enzyme-inducing antiseizure medications on the risk of sub-therapeutic concentrations of direct oral anticoagulants: a retrospective cohort study. CNS Drugs. 2021;35(3):305–16.
留言 (0)